{"id":49346,"date":"2025-11-28T21:07:41","date_gmt":"2025-11-28T13:07:41","guid":{"rendered":"https:\/\/flcube.com\/?p=49346"},"modified":"2025-11-28T21:07:43","modified_gmt":"2025-11-28T13:07:43","slug":"juventas-car-t-wins-second-china-approval-for-lymphoma-expands-hematology-franchise","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49346","title":{"rendered":"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Juventas Cell Therapy Ltd.<\/strong> announced that <strong>inaticabtagene autoleucel (CNCT 19)<\/strong>, China\u2019s first self\u2011developed <strong>CD19\u2011targeting CAR\u2011T cell therapy<\/strong>, received <strong>New Drug Application (NDA) approval<\/strong> from the <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>relapsed or refractory large B\u2011cell lymphoma (r\/r LBCL)<\/strong> after two or more lines of systemic therapy, marking the product\u2019s <strong>second major indication<\/strong> following its November\u202f2023 approval for adult r\/r B\u2011cell acute lymphoblastic leukemia (r\/r B\u2011ALL).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>inaticabtagene autoleucel (CNCT 19)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Juventas Cell Therapy Ltd.<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>r\/r LBCL after \u22652 prior systemic therapies<\/td><\/tr><tr><td><strong>First Approval<\/strong><\/td><td>r\/r B\u2011ALL (adult) \u2013 November\u202f2023<\/td><\/tr><tr><td><strong>Technology Origin<\/strong><\/td><td>Institute of Hematology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College Hospital<\/td><\/tr><tr><td><strong>Key Innovation<\/strong><\/td><td>Globally unique <strong>CD19 scFv (HI19a)<\/strong> structure; complete independent IP rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Autologous CD19\u2011targeted CAR\u2011T cells engineered with proprietary <strong>HI19a single\u2011chain variable fragment<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Internationally leading processes; closed\u2011system automation reducing vein\u2011to\u2011vein time to <strong>14\u201116 days<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> First <strong>fully China\u2011owned CD19 CAR\u2011T<\/strong> with complete IP independence; addresses both <strong>leukemia and lymphoma<\/strong> within a single platform<\/li>\n\n\n\n<li><strong>Clinical Validation:<\/strong> Successive approvals validate platform\u2019s versatility and manufacturing consistency<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China LBCL Incidence<\/strong><\/td><td>~<strong>85,000<\/strong> new cases annually (2024)<\/td><\/tr><tr><td><strong>r\/r LBCL Eligible for CAR\u2011T<\/strong><\/td><td>~<strong>25%<\/strong> (21,000 patients)<\/td><\/tr><tr><td><strong>China CAR\u2011T Market Size<\/strong><\/td><td>\u00a56.5\u202fbillion (US$890\u202fmillion)<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>35% (2024\u20112030)<\/td><\/tr><tr><td><strong>Peak Sales Forecast (CNCT 19)<\/strong><\/td><td><strong>\u00a52.8\u20113.5\u202fbillion<\/strong> (~US$380\u2011480\u202fmillion) by 2031<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>25\u201130% of CD19 CAR\u2011T segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competition:<\/strong> Competes with <strong>Fosun Kite\u2019s Yescarta<\/strong> (imported) and <strong>BMS\u2019s Breyanzi<\/strong> (pending China approval); Juventas\u2019s <strong>local manufacturing<\/strong> and <strong>lower cost<\/strong> (\u00a5300,000\u2011350,000 vs. \u00a51.2\u202fmillion for Yescarta) provide pricing advantage<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Dual indication approval positions Juventas as <strong>leader in hematologic CAR\u2011T<\/strong>; potential for <strong>NRDL inclusion<\/strong> in 2026<\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> Pediatric r\/r B\u2011ALL Phase\u202fII data <strong>Q2\u202f2026<\/strong>; potential <strong>global partnership<\/strong> discussions for ex\u2011China rights<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding inaticabtagene autoleucel\u2019s commercial launch, market penetration, and pipeline expansion. Actual results may differ materially due to risks including competitive dynamics, manufacturing scalability, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China\u2019s first self\u2011developed CD19\u2011targeting CAR\u2011T&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49352,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[77,1137,15],"class_list":["post-49346","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-juventas-cell-therapy","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China\u2019s first self\u2011developed CD19\u2011targeting CAR\u2011T cell therapy, received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for relapsed or refractory large B\u2011cell lymphoma (r\/r LBCL) after two or more lines of systemic therapy, marking the product\u2019s second major indication following its November\u202f2023 approval for adult r\/r B\u2011cell acute lymphoblastic leukemia (r\/r B\u2011ALL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49346\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise\" \/>\n<meta property=\"og:description\" content=\"Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China\u2019s first self\u2011developed CD19\u2011targeting CAR\u2011T cell therapy, received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for relapsed or refractory large B\u2011cell lymphoma (r\/r LBCL) after two or more lines of systemic therapy, marking the product\u2019s second major indication following its November\u202f2023 approval for adult r\/r B\u2011cell acute lymphoblastic leukemia (r\/r B\u2011ALL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49346\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-28T13:07:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-28T13:07:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise\",\"datePublished\":\"2025-11-28T13:07:41+00:00\",\"dateModified\":\"2025-11-28T13:07:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2802.webp\",\"keywords\":[\"Cell-therapy\",\"Juventas Cell Therapy\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49346#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49346\",\"name\":\"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2802.webp\",\"datePublished\":\"2025-11-28T13:07:41+00:00\",\"dateModified\":\"2025-11-28T13:07:43+00:00\",\"description\":\"Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China\u2019s first self\u2011developed CD19\u2011targeting CAR\u2011T cell therapy, received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for relapsed or refractory large B\u2011cell lymphoma (r\\\/r LBCL) after two or more lines of systemic therapy, marking the product\u2019s second major indication following its November\u202f2023 approval for adult r\\\/r B\u2011cell acute lymphoblastic leukemia (r\\\/r B\u2011ALL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49346\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49346#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise - Insight, China&#039;s Pharmaceutical Industry","description":"Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China\u2019s first self\u2011developed CD19\u2011targeting CAR\u2011T cell therapy, received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for relapsed or refractory large B\u2011cell lymphoma (r\/r LBCL) after two or more lines of systemic therapy, marking the product\u2019s second major indication following its November\u202f2023 approval for adult r\/r B\u2011cell acute lymphoblastic leukemia (r\/r B\u2011ALL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49346","og_locale":"en_US","og_type":"article","og_title":"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise","og_description":"Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China\u2019s first self\u2011developed CD19\u2011targeting CAR\u2011T cell therapy, received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for relapsed or refractory large B\u2011cell lymphoma (r\/r LBCL) after two or more lines of systemic therapy, marking the product\u2019s second major indication following its November\u202f2023 approval for adult r\/r B\u2011cell acute lymphoblastic leukemia (r\/r B\u2011ALL).","og_url":"https:\/\/flcube.com\/?p=49346","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-28T13:07:41+00:00","article_modified_time":"2025-11-28T13:07:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49346#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49346"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise","datePublished":"2025-11-28T13:07:41+00:00","dateModified":"2025-11-28T13:07:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49346"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49346#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2802.webp","keywords":["Cell-therapy","Juventas Cell Therapy","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49346#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49346","url":"https:\/\/flcube.com\/?p=49346","name":"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49346#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49346#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2802.webp","datePublished":"2025-11-28T13:07:41+00:00","dateModified":"2025-11-28T13:07:43+00:00","description":"Juventas Cell Therapy Ltd. announced that inaticabtagene autoleucel (CNCT 19), China\u2019s first self\u2011developed CD19\u2011targeting CAR\u2011T cell therapy, received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for relapsed or refractory large B\u2011cell lymphoma (r\/r LBCL) after two or more lines of systemic therapy, marking the product\u2019s second major indication following its November\u202f2023 approval for adult r\/r B\u2011cell acute lymphoblastic leukemia (r\/r B\u2011ALL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49346#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49346"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49346#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2802.webp","width":1080,"height":608,"caption":"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49346#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Juventas CAR-T Wins Second China Approval for Lymphoma, Expands Hematology Franchise"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49346"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49346\/revisions"}],"predecessor-version":[{"id":49353,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49346\/revisions\/49353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49352"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}